Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2011-06-07
2011-06-07
Saeed, Kamal A (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
07956197
ABSTRACT:
Methods of using di, tri, and tetracyclic acylhydrazide derivatives and analogs, as well as pharmaceutical compositions containing the same, for the treatment or prophylaxis of viral infections and diseases associated therewith, particularly those viral infections and associated diseases caused by the orthopoxvirus.
REFERENCES:
patent: 4029666 (1977-06-01), Weber et al.
patent: 4061763 (1977-12-01), Shepard et al.
patent: 4173646 (1979-11-01), Shepard et al.
patent: 6433016 (2002-08-01), Georgiev
patent: 7687641 (2010-03-01), Jordan et al.
patent: 2002/0193443 (2002-12-01), Georgiev
patent: 2007/0287735 (2007-12-01), Jordan et al.
patent: 2008/0103181 (2008-05-01), Jordan et al.
patent: WO6412931 (1964-07-01), None
patent: WO02067939 (2002-09-01), None
patent: WO2004112718 (2004-12-01), None
patent: WO2008079159 (2008-07-01), None
patent: WO2008130348 (2008-10-01), None
Continuation-in-part Co-pending U.S. Appl. No. 11/785,998, filed Apr. 23, 2007, inventor(s) Robert F. Jordan et al.
Continuation-in-part Co-pending U.S. Appl. No. 11/785,997, filed Apr. 23, 2007, inventor(s) Robert F. Jordan et al. which is now allowed.
Ishitobi et al. “Re-examination of the Cycloaddition of Cycloheptatriene with Maleic Anhydride” Bulletin of the Chemical Society of Japan, vol. 44, 2993-3000 (1971).
Henderson et al., “Smallpox as a Biological Weapon,” JAMA 281:2127-2137 American Medical Association, (1999).
Downie et al., “The Antibody Response in Man Following Infection With Viruses of the POX Group,” J. Hyg. 56:479-487 (1958).
Moss, “Poxviridae and Their Replication,” Virology, Chapter 74:2079-2111, (1990) Raven Press, Ltd, NY.
Modlin, “Vaccinia(Smallpox)Vaccine, Recommendations of the Advisory Committee on Immunization Practices(ACIP), 2001” MMWR (Morb Mort Wkly Rep) 50:1-25 (2001).
Engler et at. “Smallpox vaccination: Risk considerations for patients with atopic dermatitis,” J. Allergy Clin Immunol. 110(3):357-365 (2002).
Jackson et al., “Expression of Mouse Interleukin-4 by a Recombinant Ectromelia Virus Suppresses Cytolytic Lymphocyte Responses and Overcomes Genetic Resistance to Mousepox,”Journal of Virology, 75(3):1205-1210, American Society for Microbiology (2001).
Bronson et al., “(S)-1-(3-Hydroxy-2-(phosphonylmethoxy)propyl)cytosine(HPMPC):a Potent Antiherpesvirus Agent,” Adv. Exp. Med. Biol. 278:277-283 (1990).
De Clercq et al, “Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines,” Antiviral Research, 8:261-272, Elsevier Science Publishers B.V. (1987).
De Oliveria et al., “Evaluation of Cidofovir(HPMPC, GS-504)against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model,” Antiviral Research 31:165-172, Elsevier Science B.V. (1996).
Snoeck et al., “Phase II Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Cidofovir Topical Gel for the Treatment of Patients with Human Papillomaviurs Infection,”CID 33:597-602 (2001).
Smee et al., “Characterization of Wild-Type and Cidofovir-Resistant Strains of Camelpox, cowpox, Monkeypox, and Vaccinia Viruses,” Antimicrobial Agents Chemotherapy 46(5)1329-1335 (2002).
Lalezari et al., “Intravenous Cidofovir for Peripheral Cytomegalovirus Retinitis in Patients with AIDS,” Ann. Intern. Med. 126(4):257-263 (1997).
De Clercq, “Vaccinia Virus Inhibitors as a Paradigm for the Chemotherapy of Poxvirus Infections,” Clinical Microbiology Reviews, 14(2):382-397 (2001).
Bauer et al., “Prophylaxis of Smallpox With Methisazone” American Journal of Epidemiology 90(2):130-145 (1969).
De Clercq et al., “Carboxyclic Adenosine Analogues As S-Adenosylhomocysteine Hydrolase Inhibitors and Antiviral Agents: Recent Advances,” Nucleosides Nucleotides 17(1-3):625-634 (1998).
Coulombe et al., “Pharmacokinetics of the antiviral agent 3-deazaneplanocin A,” European Journal of Drug Metabolism Pharmacokinets 20(3):197-202 (1995).
Obara et al., “New Neplanocin Analogues. 7. Synthesis and Antiviral Activity of 2-Halo Derivatives of neplanocin A,” J. Med. Chem. 39:3847-3852 (1996).
Co-pending U.S. Appl. No. 12/643,641; Inventor Robert R. Jordan et al.; filed Dec. 21, 2009.
CAS RN 492455-97-7 STN Entry Date Feb. 20, 2003.
CAS RN 492426-98-9 STN Entry Date Feb. 20, 2003.
CAS RN 488821-91-6 STN Entry Date Feb. 12, 2003.
CAS RN 432022-17-8 STN Entry Date Jun. 19, 2002.
CAS RN 432022-16-7 STN Entry Date Jun. 19, 2002.
CAS RN 340982-60-7 STN Entry Date Jun. 14, 2001.
CAS RN 331632-70-3 STN Entry Date Apr. 17, 2001.
CAS RN 329912-01-8 STN Entry Date Apr. 4, 2001.
CAS RN 329775-41-9 STN Entry Date Apr. 3, 2001.
CAS RN 329717-02-4 STN Entry Date Apr. 2, 2001.
CAS RN 329368-29-8 STN Entry Date Apr. 1, 2001.
CAS RN 329362-05-2 STN Entry Date Apr. 1, 2001.
CAS RN 316383-22-9 STN Entry Date Jan. 24, 2001.
Kohler, E.P. et al “The preparation of cyclic ketones by ring enlargement”, Journal of the American Chemical Society, 1939, vol. 16, pp. 1057-1061.
Ishitobi et al. “Re-examination of the Cycloaddition of Cycloheptatriene with Maleic Anhydride”, Bulletin of the Chemical Society of Japan, 1971, vol. 44, pp. 2993-3000.
Kurtz, D.W. et al, “A valence isomer trapping procedure for introductory organic laboratory”, Journal of Chemical Education , 1989, vol. 66, pp. 873-874.
Schueler, P.E. et al., “Synthesis and relative stereochemical assignment of the four isomeric cyclopropane-bridged tricyclo[3.2.2.02l4-nonan-6-0ls”, Journal of Organic Chemistry, 1974, vol. 39, pp. 2063-2069.
Blumel , J. et al., “Metallated bicyclo[3.2.2]nona-2,6,8-trienes, their rearrangement to barbaralenes, and a short syntheseis of the bicyclo[3 .2.2]nona-2,6,8-trien-4-yl anion” , Chemische Berichte , 1993, vol. 12, pp. 1283-1290.
Supplementary European Search Report EP Application No. 04776765, Dated Jul. 30, 2008.
Shiva Mohan Verma: “restricted rotations in configurational assignments:the diels-alder adduct of I,3,5-cycloheptatriene and maleic anhydride.” Recueil Des Travaux Chimiques Despays-Bas.,vol. 97, No. 9, Sep. 1978,pp. 238-241, XP002490138 Nlelsevier Science Publishers. Amsterdam. p. 238-239.
Chemical Abstracts, vol. 62, No. 37, 1965 Columbus, Ohio, US; abstract No. 529g, col. 1, XP002490139.
Office Action Dated Sep. 14, 2009, U.S. Appl. No. 10/561,153, filed Apr. 6, 2006, Inventor Jordan et al.
Office Action Dated May 6, 2007, U.S. Appl. No. 11/785,997, filed Apr. 23, 2007, Inventor Jordan et al.
Co-pending U.S. Appl. No. 12/643,641, filed Dec. 21, 2009, Inventor(s) Jordan et al.
Indian Journal of Chemistry, S.M. Verma & C. Koteswara Rao, 1975, 13(12), 1278-1281.
Journal of the Royal Netherlands Chemical Society, 1978, 97(9), 238-248.
Japanese Laid-Open Patent Publication No. S39-12931, Feb. 27, 1962.
Japanese Laid-Open Patent Publication No. S52-47844, Apr. 16, 1997.
Indian Journal of Chemistry, Hawaldar Maurya & S.M. Verma, Section B, 1986, 25B(5), 542-544.
Chem. Pharm. Bull., Masao Ishikawa, et al., 1968, 16(4), 618-621.
Japanese Laid-Open Patent Publication No. H05-140100, Jun. 8, 1993.
Indian Journal of Chemistry, 1977, 15B(8), 700-702.
Japanese Laid-Open Patent Publication No. S64-83065, Mar. 28, 1989.
Bailey Thomas R.
Jordan Robert
Rippin Susan R.
Bianchi Kristin
Kramer Levin Naftalis & Frankel LLP
Saeed Kamal A
Siga Technologies, Inc.
LandOfFree
Compounds, compositions and methods for treatment and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds, compositions and methods for treatment and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds, compositions and methods for treatment and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2712733